To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch KBLAM, WUXIBIO, INNOVENT, GENSCRIPT and AKESO Stock Futures on the Futures market. These new listings offer a flexible and efficient way to gain exposure to some of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.

Futures Trading Details

Introduction

KBLAM: Kingboard Laminates Holdings Limited is an investment holding company primarily engaged in the manufacturing and sales of copper-clad laminates. The company operates through three segments: Manufacturing and Sales of Copper-Clad Laminates; Property Management; Property Sales, Leasing, and Hotel Accommodation; and Investment Management; and Bond Investment, among other businesses.

WUXIBIO: WuXi Biologics Inc. is an investment holding company primarily engaged in providing end-to-end solutions and services for the discovery, development, and manufacturing of biological products to clients in the biopharmaceutical industry. The company operates primarily through two segments: the Biopharmaceuticals segment focuses on the discovery, development, and manufacturing of biologics; and the WuXi Consortium (XDC) segment provides contract research, development, and manufacturing organization (CRDMO) services for antibody-drug conjugates (ADCs) and various biodrug conjugates. The company primarily operates in domestic and international markets.

INNOVENT: nnovent Biologics is an investment holding company primarily engaged in the research, development, production, and marketing of innovative drugs for the treatment of major diseases such as oncology, cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmological diseases. Drug formulations include monoclonal antibodies, multispecific antibodies, immune cytokines, antibody-drug conjugates (ADCs), cell therapy, and small molecule drugs. The company's main products include Tyvyt (sintilimab injection), Davogene (bevacizumab injection), Sulixin (adalimumab injection), Dabohua (rituximab injection), and Dabertan (pemitinib tablets). The company primarily operates in the Chinese domestic and overseas markets.

GENSCRIPT: It is an investment holding company primarily engaged in the production and sales of life science research products and services. The company operates through five divisions. The Life Science Services and Products division provides a comprehensive range of research services and products.

AKESO: An investment holding company dedicated to the research, development, production, and commercialization of antibody drugs that are affordable for patients worldwide. The company's pipeline covers multiple areas, including oncology, autoimmune diseases, and metabolic disorders.

🎉 Limited-Time Offer: Enjoy 0 Trading Fees